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Abstract
Diabetes mellitus (DM) and abnormal glucose metabolism are associated with cardiovascular (CV) disease. We investigated 
the prevalence and prognostic importance of dysglycaemia in patients with acute coronary syndromes (ACS) in the PLATelet 
inhibition and patient Outcomes (PLATO) trial. Diabetes was deined as known diabetes or HbA1c ≥ 6.5% or non-fasting 
glucose ≥ 11.1 mmol/L on admission, prediabetes as HbA1c ≥ 5.7% but < 6.5%, and no diabetes as HbA1c < 5.7%. The 
primary endpoint was the composite of CV death, spontaneous myocardial infarction type 1 (sMI) or stroke at 12 months. 
Multivariable Cox regression models, adjusting for baseline characteristics, and biomarkers NT-proBNP and troponin I, 
were used to explore the association between glycaemia and outcome. On admission, 16,007 (86.1%) patients had HbA1c 
and/or glucose levels available and were subdivided into DM 38.5% (6160) (1501 patients had no previous DM diagnosis), 
prediabetes 38.8% (6210), and no DM 22.7% (3637). Kaplan Meier event rates at 12 months for CV death, sMI or stroke per 
subgroups were 14.5% (832), 9.0% (522), and 8.5% (293), respectively with multivariable adjusted HRs, versus no diabetes, 
for diabetes: 1.71 (1.50–1.95) and for prediabetes 1.03 (0.90–1.19). Corresponding event rates for CV death were 6.9% (391), 
3.4% (195) and 3.0% (102), respectively, with adjusted HRs for patients with DM of: 1.92 (1.42–2.60) and for prediabetes 
1.02 (0.79–1.32). Abnormal glucose metabolism is common in ACS patients, but only patients with deinite DM have an 
increased CV risk, indicating that prediabetes is not immediately associated with worse CV outcomes.
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Highlights
• Abnormal glucose metabolism is common in ACS 
patients.
• Patients with deinite diabetes have a doubled CV risk 
during the irst year after an ACS event.
• However, prediabetes is not immediately associated 
with worse CV outcomes during up to one year of fol-
low up.
• Although prediabetes is important to diagnose, the CV 
risk is not increased, compared with normoglycemic 
patients, during the irst year after ACS.
Introduction
Diabetes mellitus (DM) is associated with a two- to four-
fold increased risk for cardiovascular (CV) events com-
pared with non-diabetics [1]. In patients without diag-
nosed DM, but with borderline increased haemoglobin 
A1c (HbA1c), heightened fasting glucose or abnormal 
glucose tolerance test, an increased risk of CV events has 
been observed in a general population [2, 3]. The impact of 
dysglycaemia on CV risk in patients with acute coronary 
syndrome (ACS) is less clear with partly conlicting results 
[2–10]. In the PLATelet inhibition and patient Outcomes 
(PLATO) trial, we evaluated the efect of the antiplatelet 
drug ticagrelor, compared to clopidogrel, in patients with 
ACS [11, 12]. We have previously reported ticagrelor to be 
both more eicacious and of similar safety compared with 
clopidogrel, irrespective of diabetes status [8]. In the cur-
rent substudy, we stratiied patients into clinically accepted 
subgroups of glycaemia based on admission non-fasting 
glucose and HbA1c to explore the impact of dysglycaemia 
on CV outcomes [3, 8].
Methods
Study population
The PLATO trial (NCT00391872) enrolled 18624 patients 
with ACS, who were randomised to either clopidogrel or 
ticagrelor treatment in addition to optimal medical ther-
apy, including aspirin, and optional invasive strategy [11, 
12]. All patients were evaluated for diabetes at baseline, 
and baseline non-fasting glucose concentration and HbA1c 
were collected. All participants provided written informed 
consent and the study complied with the declaration of 
Helsinki. The study was approved by all local Ethics Com-
mittees and Institutional Review Boards.
Laboratory analysis
The details of laboratory sampling and handling have pre-
viously been published [11, 12].
Plasma glucose and HbA1c concentrations were deter-
mined with sandwich immunoassays on the Cobas® Ana-
lytics e601 Immunoanalyzer (Roche Diagnostics, Man-
nheim, Germany) at the Uppsala Clinical Research Center 
laboratory, Uppsala, Sweden.
Deinitions of outcome events and glycaemia 
subgroups
The primary endpoint of the present biomarker substudy 
was the composite of CV death, stroke or spontaneous 
myocardial infarction (sMI) within one year of follow up. 
sMI was deined in accordance with the universal deini-
tion of myocardial infarction (MI), hence a non-procedure-
related, non-fatal, MI type 1 [13].
DM was deined as patients with known diabetes or 
admission HbA1c ≥ 6.5% (≥ 48 mmol/mol), or non-fast-
ing venous glucose ≥ 11.1 mmol/L on admission. Pre-DM 
was deined as patients with HbA1c ≥ 5.7% but < 6.5% 
(≥ 39 mmol/mol but < 48 mmol/mol) [3]. Patients with 
HbA1c < 5.7% were considered to have neither DM nor 
pre-DM (referred to here as ‘non-diabetes’) [3].
Statistical analysis
Baseline characteristics were presented by subgroups 
of glycaemia, and compared using chi-square or 
Kruskal–Wallis tests. Kaplan Meier event rates at 1-year, 
overall and by glycaemic subgroups, were estimated. 
The associations between glycaemic subgroups, with the 
non-diabetes group as reference, and the outcomes were 
assessed by Cox proportional hazard models. Unadjusted 
and adjusted hazard ratios were derived. Adjustment 
variables included baseline characteristics (age, gender, 
smoking status, type of ACS, and history of angina, MI, 
hypercholesterolemia, diabetes, hypertension, chronic kid-
ney disease, previous; percutaneous coronary intervention 
(PCI), coronary artery bypass grafting (CABG); stroke or 
transient ischemic attack (TIA), as well as log transformed 
biomarkers; NT-pro-BNP and hs-troponin I. p-values less 
than 0.05 were considered statistically signiicant results. 
Statistical analyses were performed with SAS 9.4 (SAS 
Institute, Cary, NC) (Fig. 1).
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Results
Information on previous DM, non-fasting glucose and/
or HbA1c, were available for 16,007 patients (85.9%). On 
admission, 6160 patients (38.5%) had DM according to 
our pre-speciied criteria, of which 1501 patients (9.4%) 
had no previous DM diagnosis, consequently new-onset 
DM. In the new-onset DM subgroup, 1076 patients had an 
HbA1c ≥ 6.5%. Another 201 individuals had non-fasting 
blood glucose above 11.1 mmol/L, but with normal HbA1c. 
A total of 224 patients had both an elevated HbA1c and non-
fasting blood glucose above 11.1 mmol/L.
Patients with DM were older, and had more comorbidities 
compared to patients without DM (Table 1). In patients with 
DM, normal HbA1c (< 5.7%) was observed in 146 patients 
(2.4%), while HbA1c was between 5.7 and 6.4% in 811 
patients (13.2%) and 4346 patients (70.5%) had an HbA1c 
of ≥ 6.5%. HbA1c was not available in 857 patients (13.9%) 
classiied as diabetic by other criteria.
In addition, 6210 (38.8%) patients had pre-DM deined 
as HbA1c concentrations of ≥ 5.7% but < 6.5%. Normal 
HbA1c concentrations (HbA1c < 5.7%) were observed in 
3637 (22.7%) of the study population.
Glycaemia subgroups and outcome
The Kaplan Meier event rates at 12 months for the combined 
endpoint of CV death, sMI or stroke per subgroups were 
12.2% (694) for patients with DM, 7.2% (409) for pre-DM 
and 6.3% (213) for patients with no DM (Table 2 and Fig 1). 
In a sensitivity analysis, all MIs (not only sMI) were evalu-
ated in the composite endpoint (CV death, MI and stroke), 
with event rates at 12 months per subgroups of 14.5% (832) 
for patients with DM, 9.0% (522) for pre-DM and 8.5% 
(293) for patients with no DM.
The association between glycaemia subgroups and the 
combination of CV death, sMI or stroke is presented in 
Table 2.
The Kaplan Meier event rates for CV death alone were: 
6.9% (391), 3.4% (195) and 3.0% (102), with adjusted HRs 
presented in Table 2.
The individual components of the composite endpoint 
were evaluated in secondary analysis and are presented in 
Table 2.
Discussion
DM is independently associated with CV events, but there 
are conlicting reports on the impact of pre-DM on outcomes 
[2–7, 9]. This may be due to diferences in the identiica-
tion, classiication, follow-up and, in some cases, a lack of 
other important prognostic variables in ACS, including hs-
troponin and NT-proBNP [5]. DM is a multifaceted syn-
drome, and the pathogenesis for CV disease may include 
macrovascular changes, endothelial cell dysfunction and 
accelerated atherosclerosis, with a subsequent increased 
risk for plaque rupture, thrombus formation and ultimately 
vessel occlusion [3].
Fig. 1  Kaplan Meier plots of 
the composite endpoint per 
glycemic subgroups
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In the current substudy, we found comorbidities to be 
more common in patients with DM, including disadvanta-
geous biomarker levels such as elevated serum creatinine 
and NT-proBNP, indicating underlying organ dysfunction. 
We did not, however, observe any differences between 
patients with pre-DM and patients without DM.
Pre-DM, deined as blood glucose concentrations higher 
than normal but not meeting the deinition of diabetes, is 
associated with an approximately 5–10% annual risk of 
developing type 2 DM [14]. When diagnosed with DM, 
the patient momentarily is considered to have heightened 
risk for adverse events, and the indication for cardiac revas-
cularisation, medical treatments e.g. ACE inhibitors, and 
luid therapy with angiography uses the presence of DM as 
a dichotomous condition [2, 3, 15]. It is, however, unknown 
if the observed heightened CV risk starts even at moderate 
levels of dysglycaemia or if abnormal glucose metabolism 
below a certain threshold may be non-pathogenic [3, 14].
In the current cohort, the proportion of patients with DM 
and at the same time a normal HbA1c was 2.5%, indicat-
ing that medical and lifestyle treatments still are not able to 
maintain normal HbA1c in patients with diabetes.
Table 1  Baseline characteristics by glycemic subgroups
a Cockcroft Gault
Characteristic Diabetic
(N = 6160)
Pre-diabetic
(N = 6210)
Non-diabetic
(N = 3637)
Overall
(N = 16,007)
p-value
Female gender 2074 (33.7%) 1703 (27.4%) 854 (23.5%) 4631 (28.9%) < 0.0001
Age, years (median, 25th–75th) 64 (56–72) 62 (54–71) 60 (51–68) 62 (54–71) < 0.0001
Weight, kg (median, 25th–75th) 81.0 (70.0–92.0) 80.0 (70.0–90.0) 78.0 (68.0–86.0) 80.0 (70.0–90.0) < 0.0001
Smoking status < 0.0001
 Non-smoker 2794 (45.4%) 2285 (36.8%) 1273 (35.0%) 6352 (39.7%)
 Ex-smoker 1674 (27.2%) 1481 (23.8%) 875 (24.1%) 4030 (25.2%)
 Habitual smoker 1692 (27.5%) 2444 (39.4%) 1489 (40.9%) 5625 (35.1%)
Systolic blood pressure (mmHg) 135 (120–150) 130 (120–150) 130 (120–149) 133 (120–150) < 0.0001
Diastolic blood pressure (mmHg) 80 (70–88) 80 (70–90) 80 (70–90) 80 (70–90) 0.0222
Medical history
 Angina pectoris 3211 (52.1%) 2734 (44.0%) 1361 (37.4%) 7306 (45.6%) < 0.0001
 Myocardial infarction 1565 (25.4%) 1180 (19.0%) 585 (16.1%) 3330 (20.8%) < 0.0001
 Percutaneous coronary intervention 1049 (17.0%) 738 (11.9%) 385 (10.6%) 2172 (13.6%) < 0.0001
 Coronary artery bypass graft 546 (8.9%) 293 (4.7%) 137 (3.8%) 976 (6.1%) < 0.0001
 Non-haemorrhagic stroke 324 (5.3%) 206 (3.3%) 99 (2.7%) 629 (3.9%) < 0.0001
 Hypertension 4827 (78.4%) 3787 (61.0%) 1977 (54.4%) 10,591 (66.2%) < 0.0001
 Dyslipidaemia 3389 (55.0%) 2706 (43.6%) 1446 (39.8%) 7541 (47.1%) < 0.0001
 Peripheral artery disease 514 (8.3%) 335 (5.4%) 165 (4.5%) 1014 (6.3%) < 0.0001
 Chronic renal disease 416 (6.8%) 180 (2.9%) 99 (2.7%) 695 (4.3%) < 0.0001
Treatment approach < 0.0001
 Invasive 4184 (67.9%) 4489 (72.3%) 2718 (74.7%) 11,391 (71.2%)
Type of ACS < 0.0001
 STEMI 2183 (35.4%) 2628 (42.3%) 1582 (43.5%) 6393 (39.9%)
Medications at the time of randomization
 Aspirin 5800 (94.2%) 5834 (93.9%) 3387 (93.1%) 15021 (93.8%) 0.1056
 Beta blockers 4307 (69.9%) 4382 (70.6%) 2545 (70.0%) 11234 (70.2%) 0.7072
 ACE inhibitors 3885 (63.1%) 3400 (54.8%) 186 (51.1%) 9145 (57.1%) < 0.0001
 Angiotensin II receptor blockers 764 (12.4%) 445 (7.2%) 247 (6.8%) 1456 (9.1%) < 0.0001
 Statins 4936 (80.1%) 4978 (80.2%) 2865 (78.8%) 12,779 (79.8%) 0.1904
Biochemistry (median, 25th–75th)
 Creatinine  clearancea (mL/min) 76.9 (58.8–96.5) 80.8 (64.1–98.5) 84.3 (67.2-102.3) 80.4 (63.0–99.0) < 0.0001
 Glucose (mmol/L) 9.3 (7.0–12.5) 6.4 (5.6–7.5) 6.1 (5.4–7.1) 6.9 (5.7–8.8) < 0.0001
 Haemoglobin A1c (%) 7.2 (6.5–8.5) 5.9 (5.8–6.1) 5.5 (5.3–5.6) 6.0 (5.7–6.6) < 0.0001
 NT-proBNP (pmol/L) 76 (24–244) 53 (18–164) 49 (17–147) 59 (19–184) < 0.0001
 High sensitivity troponin I (ng/Lµg/L) 2.0 (0.2–11.8) 2.0 (0.2–12.0) 2.2 (0.2–12.2) 2.1 (0.2–12.0) 0.4910
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The increased CV risk for patients with manifest DM 
was, however, not observed in patients with pre-DM during 
the irst year after ACS, and we believe this highlights that 
a direct efect of hyperglycaemia on clinical outcome may 
not be present, rather the deleterious hyperglycaemic efects 
may arise after a prolonged and accumulated exposure to 
dysglycemia.
Limitations
Manifest DM was one of several enrichment criteria 
employed to enter the PLATO trial if presenting with a 
non-STEACS [11, 12]. It is likely that the current popula-
tion exhibited a larger proportion of patients with diagnosed 
DM than other ACS populations, and consequently propor-
tionally smaller subgroups of patients with pre-DM and no 
DM. Although follow up was up to one year, the detrimen-
tal efect of DM was not observed within the irst year of 
diagnosis in the current study, however this study was not 
designed to answer these important questions.
Conclusions
Abnormal glucose metabolism is common in patients with 
ACS and 9% of the PLATO study patients had undiagnosed 
diabetes. Although the overall event rate during the irst year 
after ACS is high, we only observed patients with deinite 
DM to have a further increased CV risk, indicating that pre-
DM is not immediately associated with worse CV outcomes 
over the irst year after ACS. Nonetheless, this inding does 
not diminish the need for close follow-up of patients with 
pre-DM in order to detect DM early, as recommended by 
international guidelines.
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